FDA approves first treatment for Niemann-Pick Type C in infants
The US Food and Drug Administration has approved cyclodextrin, marketed as Adrabetadex, marking the first targeted therapy for infants with Niemann-Pick Type C disease. The rare genetic disorder causes fatal neurological decline because missing proteins allow cholesterol and lipids to build up inside cells. Built on two decades of foundational basic research led by National Institutes of Health scientists and Beren Therapeutics, the therapy directly enables intracellular lipid transport. In international clinical trials, the drug prevented neurodegeneration and significantly extended survival in infants, offering long-awaited relief to families.
National Institutes of Health ยท Nov 17, 2026
Read on The Whole Day →